[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356048-105":59,"doc-detail-356048-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","phase-12-study-of-incagn01876-an-anti-glucocorticoid-induced-tumor-necrosis-factor-receptor-agonist-monoclonal-antibody-plus-immunotherapy-for-advanced-cancers","Phase 1/2 Study of INCAGN01876 - An Anti-Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist Monoclonal Antibody, Plus Immunotherapy for Advanced Cancers","","Immune checkpoint–based immunotherapy aims to counter tumor-mediated immunosuppression in solid tumors. INCAGN01876 is a humanized IgG1 monoclonal antibody targeting glucocorticoid-induced tumor necrosis factor receptor (GITR). This phase 1/2 trial assessed INCAGN01876 combined with nivolumab and/or ipilimumab in patients with advanced malignancies. Phase 1 used dose escalation, while phase 2 expanded cohorts using safety and response outcomes, reporting overall tolerability and antitumor activity alongside defined endpoints.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/phase-12-study-of-incagn01876-an-anti-glucocorticoid-induced-tumor-necrosis-factor-receptor-agonist-monoclonal-antibody-plus-immunotherapy-for-advanced-cancers/356048/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/phase-12-study-of-incagn01876-an-anti-glucocorticoid-induced-tumor-necrosis-factor-receptor-agonist-monoclonal-antibody-plus-immunotherapy-for-advanced-cancers/356048.png","ImageObject",300,407,{"name":92,"@type":93},"awa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is INCAGN01876 and what immune target does it engage?","Question",{"text":112,"@type":113},"INCAGN01876 is a humanized IgG1 monoclonal antibody that targets GITR, a costimulatory receptor involved in regulating T-cell activity and immune responses.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the phase 1/2 study structured and what were the primary endpoints?",{"text":117,"@type":113},"Phase 1 used dose escalation and focused on safety, while phase 2 expanded selected tumor cohorts; phase 2 primary endpoints included objective response rate (ORR) alongside safety.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key safety and efficacy findings reported?",{"text":121,"@type":113},"INCAGN01876 combinations were generally well tolerated, with treatment-emergent adverse events occurring in 62.8% of patients and grade ≥3 events in 13.8%. Antitumor activity was observed in specific TGF cohorts, including SCCHN and cervical cancer.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356048,1790230092,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},3985747858093,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Phase 1/2 study of INCAGN01876, an anti-glucocorticoidinduced tumor necrosis factor receptor agonist monoclonal antibody, plus immunotherapy for advanced cancers  \nOmid Hamid1, , Frederic Forget2, Melissa Johnson3, Thomas J. George4, Nawel Bourayou5, Sonia Ioannidis5, Feng Zhou6, Hong Yang6, Zhiwan Dong6, Martin E. Gutierrez7,*,   \n1The Angeles Clinic and Research Institute, A Cedars Sinai Affiliate, Los Angeles, CA, 90025, United States  \n2Centre Hospitalier de l‘Ardenne, Libramont-Chevigny, 6800, Belgium 3Sarah Cannon Research Institute, Nashville, TN, 37203, United States 4 University of Florida, Gainesville, FL, 32610, United States  \n5 Incyte Biosciences International Srl, Morges, 1110, Switzerland 6 Incyte Corporation, Wilmington, DE, 19803, United States  \n7John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, 07601, United States  \n*Corresponding author: Martin E. Gutierrez, MD, John Theurer Cancer Center, Hackensack University Medical Center, 92 2nd Street, Hackensack, NJ 07601, USA ([martin.gutierrez@hmhn.org](martin.gutierrez@hmhn.org)) .  \nAbstract  \nBackground: Modulating tumor-mediated immunosuppression with immunotherapies is an effective therapeutic approach for solid tumors. INCAGN01876 is a humanized IgG1 anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody. This phase 1/2 trial evaluated INCAGN01876 plus nivolumab and/or ipilimumab for advanced malignancies.  \nMethods: In phase 1 (dose escalation), patients received various INCAGN01876 plus nivolumab and/or ipilimumab regimens. In phase 2 (dose expansion), patients with select tumors received INCAGN01876 plus ipilimumab (treatment group [TG] C2) or INCAGN01876 plus nivolumab (TGF). Primary endpoints: safety (phase 1), objective response rate (ORR; phase 2).  \nResults: Overall, 145 patients were enrolled: 51 and 94 in phases 1 and 2, respectively (TGC2, n = 8; TGF, n = 86 [squamous cell carcinoma of the head and neck, SCCHN, n = 46]). Four patients had dose-limiting toxicities; maximum tolerated dose was not reached; INCAGN01876 300 mg Q2W was selected as the recommended phase 2 dose based on safety with nivolumab and/or ipilimumab and safety and pharmacokinetic/pharmacodynamic monotherapy data from the INCAGN 1876-101 phase 1 study. INCAGN01876-related treatment-emergent adverse events (TEAEs) occurred in 62.8% of patients (most commonly pruritus, 16.6%); grade ≥3, 13.8%. Immune-related TEAEs occurred in 31.0% of patients (most frequently pruritus, 11.7%) most were (75.6%) grade 1/2 events. Antitumor activity was observed in TGF cohorts with SCCHN or cervical cancer (ORR 23.9% and 16.7%, respectively).  \nConclusion: INCAGN01876 plus nivolumab and/or ipilimumab was generally well tolerated, with a safety profile consistent with previous reports. This observation, along with encouraging antitumor activity in SCCHN and cervical cancer, supports development of INCAGN01876 combined with immune checkpoint inhibitors.  \nKey words: nivolumab; ipilimumab; monoclonal antibody; head and neck neoplasms; neoplasm metastasis; immunotherapy  \nReceived: January 21, 2026. Accepted: June 9, 2026 © The Author(s) 2026. Published by Oxford University Press.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.  \nImplications for Practice  \nSimultaneous targeting of multiple immune checkpoints is a proposed solution to ICI treatment resistance (eg, PD-1/PD-L1 and CTLA-4) . GITR agonists act through promoting effector T-cell activity while inhibiting regulatory T-cell immunosuppressive activity. The distinct mechanisms of action from PD-1 and CTLA-4 may augment their effects, offering a novel treatment option. Here, INCAGN01876, a humanized GITR-targeti","cbCaiiNKNwW5Pg3v","https://ap.wps.com/l/cbCaiiNKNwW5Pg3v","pdf",1331721,12,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Implications for Practice\n# Introduction","[{\"question\":\"What is INCAGN01876 and what immune target does it engage?\",\"answer\":\"INCAGN01876 is a humanized IgG1 monoclonal antibody that targets GITR, a costimulatory receptor involved in regulating T-cell activity and immune responses.\"},{\"question\":\"How was the phase 1/2 study structured and what were the primary endpoints?\",\"answer\":\"Phase 1 used dose escalation and focused on safety, while phase 2 expanded selected tumor cohorts; phase 2 primary endpoints included objective response rate (ORR) alongside safety.\"},{\"question\":\"What were the key safety and efficacy findings reported?\",\"answer\":\"INCAGN01876 combinations were generally well tolerated, with treatment-emergent adverse events occurring in 62.8% of patients and grade ≥3 events in 13.8%. Antitumor activity was observed in specific TGF cohorts, including SCCHN and cervical cancer.\"}]","Phase 1/2 Study of INCAGN01876 - An Anti-Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist Monoclonal Antibody, Plus Immunotherapy for Advanced Cancers | PDF",1790122979,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1436ede6cdb0fd0bfd0064a4b35ce971.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/add9a183ecfea35dd18202a71080f50e.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e031fe5f81a8063ed04583ce3f6d7db.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c4104cc82b5cdb8d93d634f7276e49ff.webp",980,1287]